Hypokalaemia and peripheral oedema in a Cushingoid patient with metastatic prostate cancer

被引：0
|
作者：
Schepers, L. M. [1 ]
Kisters, J. M. H. [1 ]
Wetzels, C. [2 ]
Creemers, G. J. [1 ]
机构：
[1] Catharina Hosp, Dept Internal Med, Eindhoven, Netherlands
[2] Jeroen Bosch Hosp, Dept Pathol, Shertogenbosch, Netherlands
来源：
NETHERLANDS JOURNAL OF MEDICINE | 2020年 / 78卷 / 06期
关键词：
Cushing's syndrome; ectopic ACTH production; large cell neuroendocrine carcinoma; prostate cancer; NEUROENDOCRINE DIFFERENTIATION;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We report on a 75-year-old man with a history of metastatic prostate cancer who presented with haematuria, peripheral oedema, metabolic alkalosis, hypokalaemia, and hypertension. Laboratory evaluation was compatible with the diagnosis of adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome and suggestive of ectopic ACTH production. Pathology of a prostate biopsy specimen showed a large cell neuroendocrine carcinoma (LCNEC) of the prostate. This report describes a case of Cushing's syndrome that was probably caused by ectopic ACTH secretion by a LCNEC of the prostate.
引用
收藏
页码：401 / 403
页数：3
相关论文
共 50 条
  • [31] Peripheral blood microRNAs expression profile: A fingerprint for metastatic prostate cancer.
    Medina Villaamil, Vanessa
    Aparicio, Guadalupe
    Santamarina Cainzos, Isabel
    Gomez-Veiga, Francisco
    Valladares Ayerbes, Manuel
    Quindos Varela, Maria
    Anton Aparicio, Luis M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Abiraterone-induced refractory hypokalaemia and torsades de pointes in a patient with metastatic castration-resistant prostate carcinoma: a case report
    Riad, Mariam
    Allison, Jeffery Scott
    Nayyal, Shahla
    Hritani, AbdulWahab
    EUROPEAN HEART JOURNAL-CASE REPORTS, 2021, 5 (12)
  • [33] In vitro culture and therapeutic profiling of patient derived metastatic prostate cancer
    Alinezhad, Saeid
    Joshi, Andre
    Rhee, Handoo
    McPherson, Stephen
    Williams, Elizabeth
    Nelson, Colleen
    Vela, Ian
    BJU INTERNATIONAL, 2018, 122 : 24 - 25
  • [34] Patient expectations of benefit from systemic treatments for metastatic prostate cancer
    Oswald, Laura B.
    Kasimer, Rachel
    Rappazzo, Katherine
    Fought, Angela J.
    Penson, David F.
    Morgans, Alicia K.
    CANCER MEDICINE, 2020, 9 (03): : 980 - 987
  • [35] A RARE CASE OF SEVERE SEQUESTRATIONAL HYPOCALCEMIA IN PATIENT WITH METASTATIC PROSTATE CANCER
    Drekolias, Dimitrios
    Gonuguntla, Karthik
    Gadela, Naga Vaishnavi
    Patil, Shivaraj
    Perosevic, Nikola
    Perosevic, Milica
    Manzoor, Kamran
    CHEST, 2020, 158 (04) : 842A - 843A
  • [36] PATIENT REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Aggarwal, S.
    Segal, J.
    Kumar, S.
    VALUE IN HEALTH, 2013, 16 (07) : A421 - A421
  • [37] Metastatic Prostate Cancer An update on treatments and a review of patient symptom management
    Drudge-Coates, Lawrence
    Delacruz, Anthony
    Gledhill, Richard
    Goh, Philiz
    Tomlinson, Brian
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2020, 24 (04) : 370 - 379
  • [38] Endocrine combination therapy for prostate and metastatic breast cancer in a male patient
    Baumgaertner, Anne K.
    Schnelzer, Andreas C.
    Harbeck, Nadia
    Kiechle, Marion
    von Steinburg, Stephanie Pildner
    BREAST CARE, 2007, 2 (01) : 37 - 39
  • [39] Individualized therapy strategies with a review of a young patient with metastatic prostate cancer
    Hu, Yuwei
    Ou, Yong
    Ren, Shangqing
    Wang, Kai
    ASIAN JOURNAL OF SURGERY, 2023, 46 (01) : 602 - 603
  • [40] Patient expectations from systemic treatment of metastatic prostate cancer (mPC).
    Moses, Kelvin A.
    Penson, David F.
    Du, Liping
    Ahmed, Ivy
    Morgans, Alicia Katherine
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345